CloneID: h15D2 (Fletikumab)
Antigen Long Description: The original antibody was generated by immunizing mice by injecting subcutaneously 20 μg of human IL-20 in FCA followed by two injections with 20 μg of hIL20 in FIA.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q9NYY1
Specificity Statement: This antibody binds a linear epitope comprising amino acids 'YQTPDHYTLRKISSLANSFLTIK' of the human Interleukin-20. It also cross reacts with mouse and cynomolgus monkey IL-20 . IL-20 is a pro-inflammatory and angiogenic cytokine mainly secreted by monocytes, granulocytes, dendritic cells and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation. IL-20 shows effects in several inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, cancer, and liver fibrosis via regulating cytokines and chemokines. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1.
Application Notes (Clone): This antibody can bind recombinant human IL-20 in an ELISA. This antibody was capable or neutralizing human IL20, cynomolgus IL20 and mouse IL20 induced proliferation of BaF-3(hIL20R) cells. This antibody can detect both native and denatured form of human IL-20 in a western blot. The original IgG4 version of this antibody, expressed in HEK293 cells, reacts with recombinant human IL-20 with a binding affinity of Kd= 32 pM (US8287861). It shows a very high potency in blocking IL-20 mediated activity on IL-20RA/IL-20RB and IL-22RA1/IL20R2 expressing cells with an IC50 value of 0.27 nM. It has a serum half-life of ~3 weeks in RA (Rheumatoid Arthritis) patients. Under the dose range from 0.05 to 3.0 mg/kg, Fletikumab was tolerable and non-toxic in patients with psoriasis. However, the clinical study was terminated because no apparent efficacy was observed. In the phase 2a trial, Fletikumab significantly reduced tender joint counts and swollen joint counts in seropositive RA patients (PMID: 30319661).
English
Deutsch
